Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more
Viking Therapeutics Inc (VKTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.133x
Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has a cash flow conversion efficiency ratio of -0.133x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-85.29 Million) by net assets ($639.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Viking Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Viking Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Viking Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Viking Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanwha Solutions
KO:009830
|
0.007x |
|
President Chain Store Corp
TW:2912
|
0.152x |
|
Kulicke and Soffa Industries Inc
NASDAQ:KLIC
|
-0.011x |
|
Adani Green Energy Limited
NSE:ADANIGREEN
|
0.150x |
|
Prada S.p.A
PINK:PRDSF
|
0.215x |
|
Fastly Inc. Cl A
LSE:0A3P
|
N/A |
|
AKERO THEREP.INC.DL-0001
F:0K4
|
N/A |
|
Gjensidige Forsikring ASA
OTCGREY:GJNSF
|
0.004x |
Annual Cash Flow Conversion Efficiency for Viking Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Viking Therapeutics Inc from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $639.06 Million | $-87.79 Million | -0.137x | -37.75% |
| 2024-12-31 | $880.28 Million | $-87.79 Million | -0.100x | +52.64% |
| 2023-12-31 | $348.42 Million | $-73.38 Million | -0.211x | +36.76% |
| 2022-12-31 | $145.32 Million | $-48.40 Million | -0.333x | -41.29% |
| 2021-12-31 | $201.88 Million | $-47.59 Million | -0.236x | -164.47% |
| 2020-12-31 | $244.34 Million | $-21.78 Million | -0.089x | +0.22% |
| 2019-12-31 | $277.12 Million | $-24.75 Million | -0.089x | -41.80% |
| 2018-12-31 | $297.75 Million | $-18.75 Million | -0.063x | +94.25% |
| 2017-12-31 | $13.46 Million | $-14.76 Million | -1.096x | +20.38% |
| 2016-12-31 | $8.04 Million | $-11.07 Million | -1.377x | -37.55% |
| 2015-12-31 | $8.72 Million | $-8.73 Million | -1.001x | -1491.52% |
| 2014-12-31 | $-22.13 Million | $-1.59 Million | 0.072x | -76.96% |
| 2013-12-31 | $-250.60K | $-78.23K | 0.312x | -- |